Healthcare [ 13/13 ] | Medical Devices [ 104/159 ]
NYSE | Common Stock
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The company markets its products through direct sales organization, as well as through distributors in the United States and internationally.
Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 21, 24 | -0.63 Decreased by -18.87% | -0.55 Decreased by -14.55% |
| Nov 1, 23 | -0.5 Decreased by -11.11% | -0.55 Increased by +9.09% |
| Aug 2, 23 | -0.55 Increased by +33.73% | -0.55 |
| May 3, 23 | -0.59 Decreased by -55.26% | -0.58 Decreased by -1.72% |
| Feb 22, 23 | -0.53 Decreased by -70.97% | -0.55 Increased by +3.64% |
| Nov 2, 22 | -0.45 Decreased by -114.29% | -0.52 Increased by +13.46% |
| Aug 3, 22 | -0.83 Decreased by -654.55% | -0.44 Decreased by -88.64% |
| May 4, 22 | -0.38 Decreased by -80.95% | -0.51 Increased by +25.49% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 82.36 M Increased by +15.64% | -36.78 M Decreased by -16.91% | Decreased by -44.65% Decreased by -1.1% |
| Sep 30, 23 | 78.05 M Increased by +9.51% | -30.44 M Decreased by -10.4% | Decreased by -39.01% Decreased by -0.81% |
| Jun 30, 23 | 80.4 M Increased by +10.61% | -32.81 M Increased by +27.94% | Decreased by -40.81% Increased by +34.86% |
| Mar 31, 23 | 73.9 M Increased by +9.19% | -34.63 M Decreased by -743.97% | Decreased by -46.86% Decreased by -689.78% |
| Dec 31, 22 | 71.23 M Decreased by -2.75% | -31.46 M Decreased by -43.84% | Decreased by -44.17% Decreased by -47.9% |
| Sep 30, 22 | 71.27 M Decreased by -4.61% | -27.58 M Decreased by -542.63% | Decreased by -38.69% Decreased by -564% |
| Jun 30, 22 | 72.69 M Decreased by -6.93% | -45.54 M Decreased by -160.47% | Decreased by -62.65% Decreased by -179.85% |
| Mar 31, 22 | 67.68 M Decreased by -0.42% | 5.38 M Increased by +132.65% | Increased by +7.94% Increased by +132.79% |